Teschner, Daniel http://orcid.org/0000-0001-7351-8060
Knop, Jana http://orcid.org/0000-0001-7879-9287
Piehl, Christian http://orcid.org/0000-0002-1054-0081
Junker, Sophia http://orcid.org/0000-0002-1434-9380
Witzke, Oliver http://orcid.org/0000-0002-1019-1301
Funding for this research was provided by:
Takeda Pharma Vertrieb GmbH & Co. KG
Article History
Received: 24 January 2022
Accepted: 3 May 2022
First Online: 28 May 2022
Declarations
:
: DT received honoraria and travel grants from ACI Clinical, BioNTech, Gilead, F2G, iQone, MSD, Octapharma, Pfizer, and Takeda, received travel grants from AbbVie, Astellas, Celgene, Jazz, and Medac, serves as a consultant for ACI Clinical, BioNTech, Gilead, iQone, MSD, Octapharma, Pfizer, and Takeda, and received research grants from Gilead. JK is an employee of Takeda Pharma Vertrieb GmbH & Co. KG. CP is an employee of Takeda Pharma Vertrieb GmbH & Co. KG and owner of Takeda shares. SJ is an employee of Ingress-Health HWM GmbH, a wholly owned subsidiary of Cytel Inc., contracted by Takeda Pharma Vertrieb GmbH & Co. KG to conduct this research. OW received research grants for clinical studies, speaker’s fees, honoraria, and travel expenses from Alexion, Amgen, Astellas, Basilea, Biotest, Bristol Myers Squibb, Chiesi, Correvio, Gilead, Hexal, Janssen, Dr. F. Köhler Chemie, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, Takeda, Teva, and UCB, as well as an Unrestricted grant of the Rudolf-Ackermann-Stiftung (Stiftung für Klinische Infektiologie).
: As the dataset was anonymized, no ethical approval and no informed consent of patients was required. The study protocol was reviewed by the data owner (AOK PLUS), who subsequently approved the analysis.